Shattuck Labs (NASDAQ:STTK) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Shattuck Labs (NASDAQ:STTK) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

STTK has been the topic of a number of other research reports. Needham & Company LLC initiated coverage on shares of Shattuck Labs in a research report on Friday, March 6th. They set a “buy” rating and a $25.00 price objective on the stock. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Monday, December 1st. Piper Sandler started coverage on shares of Shattuck Labs in a research note on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target for the company. Citigroup upped their price target on shares of Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a report on Friday, March 13th. Finally, Wedbush increased their price objective on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $6.02 on Friday. The company has a market cap of $430.79 million, a P/E ratio of -7.82 and a beta of 1.55. The business’s 50 day moving average price is $4.73 and its 200-day moving average price is $3.35. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $6.81.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of ($1.00) million for the quarter, compared to analysts’ expectations of $0.17 million. As a group, equities analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently modified their holdings of STTK. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Shattuck Labs during the third quarter valued at approximately $29,000. Virtu Financial LLC bought a new position in Shattuck Labs in the third quarter worth approximately $38,000. AQR Capital Management LLC grew its stake in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in Shattuck Labs during the 2nd quarter worth $44,000. Finally, Squarepoint Ops LLC purchased a new position in Shattuck Labs during the 3rd quarter worth $46,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.